Literature DB >> 24768348

Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers.

Claudia Blattner1, Jeong Hyun Lee2, Kwinten Sliepen3, Ronald Derking3, Emilia Falkowska4, Alba Torrents de la Peña3, Albert Cupo5, Jean-Philippe Julien2, Marit van Gils3, Peter S Lee6, Wenjie Peng7, James C Paulson7, Pascal Poignard4, Dennis R Burton8, John P Moore5, Rogier W Sanders9, Ian A Wilson10, Andrew B Ward11.   

Abstract

All previously characterized broadly neutralizing antibodies to the HIV-1 envelope glycoprotein (Env) target one of four major sites of vulnerability. Here, we define and structurally characterize a unique epitope on Env that is recognized by a recently discovered family of human monoclonal antibodies (PGT151-PGT158). The PGT151 epitope is comprised of residues and glycans at the interface of gp41 and gp120 within a single protomer and glycans from both subunits of a second protomer and represents a neutralizing epitope that is dependent on both gp120 and gp41. Because PGT151 binds only to properly formed, cleaved trimers, this distinctive property, and its ability to stabilize Env trimers, has enabled the successful purification of mature, cleaved Env trimers from the cell surface as a complex with PGT151. Here we compare the structural and functional properties of membrane-extracted Env trimers from several clades with those of the soluble, cleaved SOSIP gp140 trimer.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24768348      PMCID: PMC4057017          DOI: 10.1016/j.immuni.2014.04.008

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  51 in total

1.  HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins.

Authors:  Yuxing Li; Sijy O'Dell; Richard Wilson; Xueling Wu; Stephen D Schmidt; Carl-Magnus Hogerkorp; Mark K Louder; Nancy S Longo; Christian Poulsen; Javier Guenaga; Bimal K Chakrabarti; Nicole Doria-Rose; Mario Roederer; Mark Connors; John R Mascola; Richard T Wyatt
Journal:  J Virol       Date:  2012-08-08       Impact factor: 5.103

2.  Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.

Authors:  Jason S McLellan; Marie Pancera; Chris Carrico; Jason Gorman; Jean-Philippe Julien; Reza Khayat; Robert Louder; Robert Pejchal; Mallika Sastry; Kaifan Dai; Sijy O'Dell; Nikita Patel; Syed Shahzad-ul-Hussan; Yongping Yang; Baoshan Zhang; Tongqing Zhou; Jiang Zhu; Jeffrey C Boyington; Gwo-Yu Chuang; Devan Diwanji; Ivelin Georgiev; Young Do Kwon; Doyung Lee; Mark K Louder; Stephanie Moquin; Stephen D Schmidt; Zhi-Yong Yang; Mattia Bonsignori; John A Crump; Saidi H Kapiga; Noel E Sam; Barton F Haynes; Dennis R Burton; Wayne C Koff; Laura M Walker; Sanjay Phogat; Richard Wyatt; Jared Orwenyo; Lai-Xi Wang; James Arthos; Carole A Bewley; John R Mascola; Gary J Nabel; William R Schief; Andrew B Ward; Ian A Wilson; Peter D Kwong
Journal:  Nature       Date:  2011-11-23       Impact factor: 49.962

Review 3.  Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies.

Authors:  Peter D Kwong; John R Mascola
Journal:  Immunity       Date:  2012-09-21       Impact factor: 31.745

4.  A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.

Authors:  Robert Pejchal; Katie J Doores; Laura M Walker; Reza Khayat; Po-Ssu Huang; Sheng-Kai Wang; Robyn L Stanfield; Jean-Philippe Julien; Alejandra Ramos; Max Crispin; Rafael Depetris; Umesh Katpally; Andre Marozsan; Albert Cupo; Sebastien Maloveste; Yan Liu; Ryan McBride; Yukishige Ito; Rogier W Sanders; Cassandra Ogohara; James C Paulson; Ten Feizi; Christopher N Scanlan; Chi-Huey Wong; John P Moore; William C Olson; Andrew B Ward; Pascal Poignard; William R Schief; Dennis R Burton; Ian A Wilson
Journal:  Science       Date:  2011-10-13       Impact factor: 47.728

Review 5.  A Blueprint for HIV Vaccine Discovery.

Authors:  Dennis R Burton; Rafi Ahmed; Dan H Barouch; Salvatore T Butera; Shane Crotty; Adam Godzik; Daniel E Kaufmann; M Juliana McElrath; Michel C Nussenzweig; Bali Pulendran; Chris N Scanlan; William R Schief; Guido Silvestri; Hendrik Streeck; Bruce D Walker; Laura M Walker; Andrew B Ward; Ian A Wilson; Richard Wyatt
Journal:  Cell Host Microbe       Date:  2012-10-18       Impact factor: 21.023

Review 6.  Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses.

Authors:  Dennis R Burton; Pascal Poignard; Robyn L Stanfield; Ian A Wilson
Journal:  Science       Date:  2012-07-13       Impact factor: 47.728

7.  Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41.

Authors:  Mei-Yun Zhang; Tingting Yuan; Jingjing Li; Andrew Rosa Borges; Jennifer D Watkins; Javier Guenaga; Zheng Yang; Yanping Wang; Richard Wilson; Yuxing Li; Victoria R Polonis; Seth H Pincus; Ruth M Ruprecht; Dimiter S Dimitrov
Journal:  PLoS One       Date:  2012-09-10       Impact factor: 3.240

8.  Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein.

Authors:  Florian Klein; Christian Gaebler; Hugo Mouquet; D Noah Sather; Clara Lehmann; Johannes F Scheid; Zane Kraft; Yan Liu; John Pietzsch; Arlene Hurley; Pascal Poignard; Ten Feizi; Lynn Morris; Bruce D Walker; Gerd Fätkenheuer; Michael S Seaman; Leonidas Stamatatos; Michel C Nussenzweig
Journal:  J Exp Med       Date:  2012-07-23       Impact factor: 14.307

9.  Antibody-based protection against HIV infection by vectored immunoprophylaxis.

Authors:  Alejandro B Balazs; Joyce Chen; Christin M Hong; Dinesh S Rao; Lili Yang; David Baltimore
Journal:  Nature       Date:  2011-11-30       Impact factor: 49.962

10.  Broad and potent neutralization of HIV-1 by a gp41-specific human antibody.

Authors:  Jinghe Huang; Gilad Ofek; Leo Laub; Mark K Louder; Nicole A Doria-Rose; Nancy S Longo; Hiromi Imamichi; Robert T Bailer; Bimal Chakrabarti; Shailendra K Sharma; S Munir Alam; Tao Wang; Yongping Yang; Baoshan Zhang; Stephen A Migueles; Richard Wyatt; Barton F Haynes; Peter D Kwong; John R Mascola; Mark Connors
Journal:  Nature       Date:  2012-09-18       Impact factor: 49.962

View more
  214 in total

Review 1.  Recent strategies targeting HIV glycans in vaccine design.

Authors:  Satoru Horiya; Iain S MacPherson; Isaac J Krauss
Journal:  Nat Chem Biol       Date:  2014-12       Impact factor: 15.040

2.  Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.

Authors:  Shilpa Patil; Rajesh Kumar; Suprit Deshpande; Sweety Samal; Tripti Shrivastava; Saikat Boliar; Manish Bansal; Nakul Kumar Chaudhary; Aylur K Srikrishnan; Kailapuri G Murugavel; Suniti Solomon; Melissa Simek; Wayne C Koff; Rajat Goyal; Bimal K Chakrabarti; Jayanta Bhattacharya
Journal:  J Virol       Date:  2016-01-13       Impact factor: 5.103

3.  A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans.

Authors:  Devin Sok; Matthias Pauthner; Bryan Briney; Jeong Hyun Lee; Karen L Saye-Francisco; Jessica Hsueh; Alejandra Ramos; Khoa M Le; Meaghan Jones; Joseph G Jardine; Raiza Bastidas; Anita Sarkar; Chi-Hui Liang; Sachin S Shivatare; Chung-Yi Wu; William R Schief; Chi-Huey Wong; Ian A Wilson; Andrew B Ward; Jiang Zhu; Pascal Poignard; Dennis R Burton
Journal:  Immunity       Date:  2016-07-19       Impact factor: 31.745

4.  Glycan Microheterogeneity at the PGT135 Antibody Recognition Site on HIV-1 gp120 Reveals a Molecular Mechanism for Neutralization Resistance.

Authors:  Laura K Pritchard; Daniel I R Spencer; Louise Royle; Snezana Vasiljevic; Stefanie A Krumm; Katie J Doores; Max Crispin
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

5.  Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans.

Authors:  Hong Zhang; Hu Fu; Robert J Luallen; Bingfen Liu; Fang-Hua Lee; Robert W Doms; Yu Geng
Journal:  Vaccine       Date:  2015-08-13       Impact factor: 3.641

6.  Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes.

Authors:  Steven W de Taeye; Gabriel Ozorowski; Alba Torrents de la Peña; Miklos Guttman; Jean-Philippe Julien; Tom L G M van den Kerkhof; Judith A Burger; Laura K Pritchard; Pavel Pugach; Anila Yasmeen; Jordan Crampton; Joyce Hu; Ilja Bontjer; Jonathan L Torres; Heather Arendt; Joanne DeStefano; Wayne C Koff; Hanneke Schuitemaker; Dirk Eggink; Ben Berkhout; Hansi Dean; Celia LaBranche; Shane Crotty; Max Crispin; David C Montefiori; P J Klasse; Kelly K Lee; John P Moore; Ian A Wilson; Andrew B Ward; Rogier W Sanders
Journal:  Cell       Date:  2015-12-17       Impact factor: 41.582

Review 7.  Computational tools for epitope vaccine design and evaluation.

Authors:  Linling He; Jiang Zhu
Journal:  Curr Opin Virol       Date:  2015-03-31       Impact factor: 7.090

Review 8.  HIV broadly neutralizing antibody targets.

Authors:  Constantinos Kurt Wibmer; Penny L Moore; Lynn Morris
Journal:  Curr Opin HIV AIDS       Date:  2015-05       Impact factor: 4.283

Review 9.  Strategies to guide the antibody affinity maturation process.

Authors:  Nicole A Doria-Rose; M Gordon Joyce
Journal:  Curr Opin Virol       Date:  2015-04-24       Impact factor: 7.090

Review 10.  Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.

Authors:  Hyun A Yi; Brian C Fochtman; Robert C Rizzo; Amy Jacobs
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.